The use of genomic sequencing panels to personalise cancer treatment is beneficial in only 5% of the patients in whom they are currently used (IMAGE)

Centro Nacional de Investigaciones Oncológicas (CNIO)

The use of genomic sequencing panels to personalise cancer treatment is beneficial in only 5% of the patients in whom they are currently used

Caption

The use of these panels following the recommended clinical criteria increases the efficacy of treatments and patient survival.

Credit

underbau / CNIO

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.